Blue Star completes MedTech business sale to Cyrix for up to Rs 40 crore

Core Business DivestedStrategic Transactions View source PDF Explain this filing

BLUESTARCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.5%Reaction day

₹1455.00

prior close

₹1458.80

announcement price

After-mkt

timing

Nifty Midcap 150market+0.5%+2.0% vs market

Household Appliances peers, median of 23sector+0.5%+2.0% vs sector

On the reaction day the stock moved 2.0 pts more than Nifty Midcap 150 and 2.0 pts more than its Household Appliances peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.4

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.5+0.5+2.0+0.5+2.0

Next day

+2.0+0.2+1.8+0.9+1.1

+2.6-0.2+2.8+0.9+1.7

+0.4-0.1+0.5+0.5-0.1

+0.1-0.5+0.7-0.4+0.5

+4.1-0.9+5.0-0.9+5.0

+1.9-3.3+5.2-5.2+7.2

15d

+7.6-2.9+10.5-3.7+11.2

+3.8-5.9+9.7-7.0+10.7

—————

UpDownMarket · Nifty Midcap 150Sector · Household Appliances peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Blue Star confirms completion of sale of its MedTech business from unit Blue Star Engineering and Electronics to Cyrix Healthcare, effective September 1, 2026. The division earned Rs 42.13 crore in FY26, about 0.33 percent of consolidated income. Total deal value up to Rs 40 crore, paid in tranches with final payment by March 31, 2027. Buyer Cyrix is unrelated to promoters and the deal is not a related-party transaction.

Likely market impact

Minor divestment sharpens focus on core engineering segments. Limited near-term financial impact given small share of consolidated income.